Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06324435 · ClinicalTrials.gov registry record · Phase 1

Apremilast for Alcohol Use Disorder Treatment in Women and Men

A Phase 1 study of Alcohol Use Disorder, sponsored by Yale University.

Active
Registry status
Phase 1
Development phase
10
Enrollment target
1
Study location

NCT06324435 is a Phase 1 study of Alcohol Use Disorder that is active but no longer recruiting, run by Yale University. The registered enrollment target is 10 participants, below the 328-participant average among 184 other Alcohol Use Disorder trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06324435, a Phase 1 study of Alcohol Use Disorder, is active but no longer recruiting, sponsored by Yale University.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
10 participants
Enrollment target
1
Study location

Study Summary

For this protocol, the investigators plan to collect pilot data to evaluate apremilast (60mg/day) in adults with Alcohol Use Disorders (AUD).

Conditions Studied

Alcohol Use Disorder

Interventions

  • DRUG Apremilast

Study Locations (1)

Connecticut

  • Yale University - New Haven

Trial Details

FieldValue
Enrollment Target 10 participants
Start Date 2024-05-08
Est. Completion 2026-08-30
Phase Phase 1

Sponsor

Yale University

1,492 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06324435

The ClinicalTrials.gov registry entry for NCT06324435 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 328-participant average among 184 other Alcohol Use Disorder trials with a reported enrollment target (97% lower). The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Alcohol Use Disorder appearing as the primary indexed condition, and to 1 intervention - of which Apremilast is the first listed.

NCT06324435 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.

Frequently Asked Questions

What is clinical trial NCT06324435 about?

NCT06324435 is a clinical study titled "Apremilast for Alcohol Use Disorder Treatment in Women and Men". For this protocol, the investigators plan to collect pilot data to evaluate apremilast (60mg/day) in adults with Alcohol Use Disorders (AUD).

What is the current status of trial NCT06324435?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2024-05-08. Estimated completion is 2026-08-30.

What conditions does trial NCT06324435 study?

This clinical trial studies the following conditions: Alcohol Use Disorder.

What interventions are being tested in trial NCT06324435?

The interventions under investigation include: Apremilast (DRUG).

Who is sponsoring clinical trial NCT06324435?

This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06324435 being conducted?

This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Alcohol Use Disorder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Alcohol Use Disorder

All registered trials for this condition

Connecticut

All trials with a study site in Connecticut

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.